Read our latest news, and find more about us and our portfolio companies.

Bird Rock Bio Announces Corporate Name Change from RuiYi, Inc.

Change reflects evolution from discovery research to global clinical development company focused on developing innovative immuno-inflammatory regulators.

ObsEva Closes CHF 60 (USD 60) Million in Series B Financing

Obseva announced the closing of a CHF 60 (USD 60) million Series B preferred equity financing. The financing included new investors HBM Healthcare Investments, New Enterprise

F-star Appoints Dr Neil Brewis as Chief Scientific Officer

Dr Brewis joins F-star from GlaxoSmithKline (GSK) where as Vice President, Head of Biopharmaceutical Research he led a global team of 300 scientists who advanced numerous monoclonal

Padlock Therapeutics - An unconventional approach to autoimmunity

Doctors have long treated autoimmune diseases such as arthritis and lupus as a case of a confused immune system: Immune cells decide healthy tissue looks foreign and wage an attack.

Canbex Therapeutics announces start of Phase II trial of VSN16R for spasticity

Canbex Therapeutics Ltd today announced that its novel orally active medication for the treatment of spasticity, VSN16R, has entered a Phase II trial in patients with spasticity

Padlock Therapeutics Appoints Adelene Perkins to Board of Directors

Veteran deal-maker and company-builder provides extensive corporate leadership and operational experience as Padlock expands its team and advances multiple programs

Padlock Therapeutics Named by FierceBiotech as a 2015 “Fierce15” Biotech Company

Padlock Therapeutics Named by FierceBiotech as a 2015 “Fierce15” Biotech Company

Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners.

Asceneuron raises CHF 30 million in a Series A financing round led by Sofinnova Partners.

RaNA Therapeutics Secures $55 Million in Oversubscribed Series B Financing

Proceeds will Further Strengthen RaNA’s Proprietary Platform s and Advance Lead Optimization and IND - Enabling Studies for Priority Programs

Padlock Therapeutics Accelerates Pipeline Development Through Agreement with GSK

Creates Industry - Leading R&D Effort Focused on Creating PAD Inhibitors for the Treatment of Autoimmune Diseases ...

Raze Therapeutics Announces Addition of Robert Copeland, PhD, to Scientific Advisory Board

Dr. Copeland brings deep experience in oncology drug discovery and development to Raze’s SAB ...

Chinese Consortium Enters into Agreement to Acquire Ambrx

The transaction is expected to close in the second quarter of 2015 ...

Gilead Sciences Acquires EpiTherapeutics

Gilead Sciences, Inc. and EpiTherapeutics ApS, a privately-held Danish company, announced the signing of a definitive agreement pursuant ...

Padlock Therapeutics Assembles Scientific Advisory Board with World Leaders in PAD Enzyme Biology and Autoimmune Disease

Company strengthens its position as a leader in developing new treatments for autoimmune disease focus ed on protein citrullination ...

Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise

Progyny, Inc., the new combined entity of Auxogyn, Inc. and Fertility Authority, LLC, announced that it has secured additional capital from investors ...

Alzheimer's Drug Discovery Foundation awarded a USD 325,000 grant to support the development of Asceneuron's tau modulators

Lausanne, Switzerland – Asceneuron SA today announced that the Alzheimer’s Drug Discovery Foundation (ADDF) awarded it a USD 325,000 grant ...

Padlock Therapeutics Initiates Collaborations with Three Leading Research Partners on the Biology of PAD Enzymes

Institutions to Conduct Disease - Specific Pre-clinical Studies With the Company’s Proprietary Investigational Compounds ...

In new Nature paper, Raze Therapeutics co-founder David Sabatini discovers role for 1C metabolism in glioblastoma

SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance ...

Raze Therapeutics Appoints Mark Manfredi as Chief Scientific Officer

Dr. Manfredi joins Raze with nearly two decades of experience in cancer biology ...

Auxogyn and Fertility Authority to Merge

Auxogyn, Inc. and Fertility Authority, LLC today announced the merger of the two companies.

The Eeva™ Test is Now Available to Help IVF Patients in the United States

The Eeva Test is now commercially available in the United States following its recent FDA clearance.

Asceneuron "The Road To Tau"

Lausanne, Switzerland – "The Road To Tau" - Asceneuron, an MS Ventures portfolio company ...

ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour

Geneva, Switzerland, 26 February 2015 – ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from ...

Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round

Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including ...

Canbex Therapeutics enters into option agreement with Ipsen

Ipsen (Euronext: IPN; ADR: IPSEY) and Canbex Therapeutics Ltd (Canbex) today announced that Canbex has granted ...

Asceneuron Appoints Leading Experts to Scientific Advisory Board

Lausanne, Switzerland - Asceneuron SA, an emerging leader in developing novel small molecule therapeutics targeting tauopathies for Alzheimer’s and ...

Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration

Evotec AG and Padlock Therapeutics, Inc. (“Padlock”) announced today that they have successfully completed an initial goal ...

Raze Therapeutics Announces Addition of Julian Adams, PhD, George Q. Daley, MD, PhD, and Karen Vousden, PhD, to Scientific Advisory Board

Members Expand Company’s Expertise in Cancer Metabolism Drug Discovery and Development